AngioDynamics (ANGO) director granted 11,887 immediately vested RSUs

Rhea-AI Filing Summary

AngioDynamics Inc director Auen Eileen O'Shea reported the acquisition of 11,887 shares of common stock, representing 11,887 restricted stock units granted as regular annual compensation for board service. These units vested immediately at grant, bringing her direct holdings to 116,605 shares of AngioDynamics common stock.

Insider Trade Summary

Net Buyer: 11,887 shares

Net Buy 1 txn

Insider Auen Eileen O'Shea

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	11,887	$0.00	$0.00

Holdings After Transaction: Common Stock — 116,605 shares (Direct)

Footnotes (1)

1. F1. The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.

Key Figures

Shares granted: 11,887 shares Price per share: $0.00 Total direct holdings after grant: 116,605 shares +1 more

4 metrics

Shares granted 11,887 shares Restricted stock units granted as regular annual director compensation

Price per share $0.00 Grant reported with transaction price per share of 0.0000

Total direct holdings after grant 116,605 shares Directly owned AngioDynamics common shares following the award

Transaction date 2026-07-15 Date of the non-derivative stock award acquisition

Key Terms

restricted stock units, regular annual compensation, non-derivative

3 terms

restricted stock units financial

"represents 11,887 restricted stock units granted as regular annual compensation"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

regular annual compensation financial

"restricted stock units granted as regular annual compensation for service as a director"

non-derivative financial

"transaction_type" is "non-derivative" for the common stock grant"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/22/2026 - 08:06 PM Accepted by SEC EDGAR 07/22/2026 - 08:06 PM Learn about SEC filing dates

FAQ

What insider transaction did Auen Eileen O'Shea report for ANGO on this Form 4?

Auen Eileen O'Shea reported the acquisition of 11,887 shares of AngioDynamics (ANGO) common stock. The shares represent restricted stock units granted as regular annual compensation for her service as a director and are not an open-market purchase.

How many AngioDynamics (ANGO) shares were granted to director Auen Eileen O'Shea and on what date?

She received 11,887 restricted stock units, corresponding to 11,887 shares of AngioDynamics common stock, on 2026-07-15. The grant is described as regular annual compensation for serving on the company’s board of directors and vested immediately upon grant.

Did Auen Eileen O'Shea pay any price per share for the 11,887 AngioDynamics (ANGO) shares?

No cash was paid; the Form 4 shows a transaction price per share of $0.00. The 11,887 shares were received as restricted stock units granted as part of her director compensation, rather than through a market purchase transaction.

What is Auen Eileen O'Shea’s total direct ownership in AngioDynamics (ANGO) after this grant?

Following the award, Auen Eileen O'Shea directly owns 116,605 shares of AngioDynamics common stock. This figure reflects her updated direct holdings after adding the 11,887 immediately vested restricted stock units from the reported compensation grant.

Were the restricted stock units granted to the AngioDynamics (ANGO) director subject to vesting conditions?

The 11,887 restricted stock units immediately vested at the time of grant. According to the disclosure, they were issued as regular annual compensation for her director service, so there is no ongoing vesting schedule tied to this specific award.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Auen Eileen O'Shea

(Last) (First) (Middle)

14 PLAZA DRIVE

(Street)

LATHAM NEW YORK 12110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		A		11,887(1)	A	$0	116,605	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The acquisition of 11,887 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") represents 11,887 restricted stock units granted as regular annual compensation for service as a director of AngioDynamics. The restricted stock units immediately vested at the time of grant.

	/s/ Lawrence T. Weiss, Attorney in Fact	07/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)